Relevance for research

For comprehensive insight into T-cell immune response research in transplant patients.

Your research into cell-mediated immunity during EBV infection has the potential to transform future approaches to EBV management in transplant patients.

QuantiFERON-EBV RUO is specifically designed for researchers studying Epstein-Barr virus and its impacts on transplant patients at increased risk. It features trusted QuantiFERON technology to measure cell-mediated immune responses to EBV infection.

T-cells are becoming increasingly recognized for their role in a wide variety of infections and immunity, the exploration of immune response markers for Epstein-Barr Virus (EBV) infections is becoming the next tool for researching their utility in transplant patients and other settings.

The QuantiFERON-EBV Blood Collection Tubes and QuantiFERON ELISA are for Research Use Only and not for diagnostic use.

Product description

The QuantiFERON-EBV BCTs SPP RUO solution is an original combination of blood collection tubes containing innovative specific peptides formulated to stimulate lymphocytes in heparinized whole blood involved in cell-mediated immunity. Plasma from the stimulated samples can then be used for detection of IFN-γ using a simple ELISA. QuantiFERON-EBV BCTs SPP RUO can unlock new research insights on the immune status of individuals at risk for EBV disease.

The workflow includes blood collection and processing to generate plasma for the detection of IFN-γ from lymphocytes involved in cell-mediated immunity. The QF-EBV Antigen BCT uses a combination of CD4+ and CD8+ antigens specific to EBV nuclear antigen proteins (EBNA-1, EBNA-3A and EBNA-3B) to stimulate lymphocytes in heparinized whole blood. QuantiFERON Nil and Mitogen BCTs are intended to be used as negative and positive controls in conjunction with the QuantiFERON-EBV Antigen BCT when workflow and donor controls are required.

The QuantiFERON-ELISA is a microplate coated with specific material for determining the concentration of IFN-γ in a human plasma sample (reported in International Units per ml; IU/ml). Analysis of results is performed using the QuantiFERON Software. Analysis software for QuantiFERON-EBV BCTs SPP RUO is available for download.

Application for research

The potential research applications of immune response assays for EBV infections include, but are not limited to:

• Investigating infection severity in hospitalized transplant patients
• Investigating patient prognosis in intensive care units
• Investigating cell-mediated immune response following EBV infection 
• Investigating immune response in patients with EBV-related malignancies (e.g., autoimmunity and cancer).

Clinical relevance

QuantiFERON Monitor (QFM) is an in vitro diagnostic test detecting interferon-γ (IFNγ) following incubation of heparinized whole blood with innate and adaptive immune response stimulants.

Product description

The assay is used to detect cell mediated immune response in immunosuppressed solid organ transplant patients.

QuantiFERON Monitor is intended for use in conjunction with risk assessment and other medical and diagnostic evaluations.

Benefits

• Assesses cell-mediated immune (CMI) response
• Provides nonpathogen-specific immune monitoring
• Complements pathogen-specific monitoring
• Aids in clinical management of solid organ transplant patients

Product description

QuantiFERON^® – CMV is a blood test that measures the immune response of CD8+ cells to CMV. The test requires the collection of three 1 mL blood samples in special antigen-coated sample tubes with subsequent ELISA analysis in the laboratory. The ELISA measures IFN gamma as a marker of a person’s ability to protect themselves against viral infection.

SSI Diagnostica distributes QuantiFERON^® CMV in Denmark, Iceland, Norway and Sweden on behalf of QIAGEN, which has developed and manufactured the test.

Benefits

• QFN CMV is the only commercial test for monitoring cellular immunity specific to CMV.
• QFN CMV is a simple test that only requires 3 x 1 mL blood samples with subsequent laboratory analysis.
• QFN CMV is a rapid test with results within 24 hours.
• QFN CMV can predict the likelihood of developing CMV disease and assist in the clinical and therapeutic treatment of transplant patients 

Clinical relevance

QuantiFERON^® TB-Gold Plus is an ELISA test for the detection of M. tuberculosis in immunocompetent individuals, for example, as part of infection detection, screening of high-risk groups, in special cases for the detection of active tuberculous disease and before treatment with immunosuppressive drugs. In the case of infection with M. tuberculosis, the immune response is predominantly cell mediated. In infected immunocompetent individuals, stimulation of blood with specific antigens (ESAT 6, CFP 10 and TB 7.7) will cause T lymphocytes to release the cytokine interferon gamma, which is detected by ELISA.

QuantiFERON-TB Gold Plus is the first TB blood test to receive certification under the European Union’s new In Vitro Diagnostic Medical Devices Regulation (IVDR).

Product description

QuantiFERON^® TB-Gold Plus consists of an ELISA kit and blood collection tubes, which can be ordered separately. For sampling, four blood collection tubes are used: 1x Nil; 2x TB Ag and 1x Mitogen. The tubes are delivered as a combined package or in bulk. In the laboratory, up to 58 tests can be performed per ELISA kit. SSI Diagnostica distributes QuantiFERON^®TB-Gold Plus in Denmark, Iceland, Norway and Sweden on behalf of QIAGEN.

Benefits

• Detection of infection with M. tuberculosis
• Result within 24 hours
• Distinguishes between infection with M. tuberculosis and BCG vaccination
• Can be easily repeated – no booster phenomenon
• Only one patient visit (compared to Mantoux test)
• High reproducibility
• Objective reading (95% CI 98-100%)
• >99% specificity and >89% (95% CI 83-93%) sensitivity